サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：COVID-19緩和製品の世界市場-2022-2029
市場調査レポート
商品コード
1140748

COVID-19緩和製品の世界市場-2022-2029

Global COVID-19 Mitigation Products Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 170 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
COVID-19緩和製品の世界市場-2022-2029
出版日: 2022年10月20日
発行: DataM Intelligence
ページ情報: 英文 170 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場力学

FDAのイニシアチブの増加が市場成長の原動力となります。

高いCOVID-19の緊急事態に伴い、FDAは医療機器メーカーや病院、グループ購買組織などのサプライチェーン内の他の人に連絡するためにいくつかの積極的な措置を取っています。FDAは、仮想デバイスとサービスに焦点を当て、世界中で1,000以上のデバイス製造拠点に接触してきました。この働きかけは、PPEや人工呼吸器などCOVID-19パンデミックの発生により需要が高まっている機器と、供給が途絶えた場合に不足する可能性がある機器の、主に2種類の仮想機器に焦点を当てたものです。FDAは、医療従事者用としてNIOSH（National Institute for Occupational Safety and Health）認可を受けていない一部の輸入使い捨て呼吸器を認可し、フィルター付き面体呼吸器の供給を増やすためのEUAを発行しました。このように、医療機器やサービスの普及に向けた取り組みや戦略が強化されていることから、市場は予測期間中に世界的に拡大すると予想されます。

地理的浸透度。

予測期間中、北米が主要な地域となっています。

北米地域は、予測期間中、世界のCOVID-19緩和製品で最大の市場シェアを占めると推定されます。米国の人口10万人あたりのコロナウイルス死亡率は、欧州のいくつかの国よりも低くなっています。2022年までに、米国のヘルスケア支出は3兆3,000億米ドルに達し、世界のヘルスケア支出の42%以上を占めるようになりました。2020年3月までに、議会は前例のない2兆2,000億米ドルのCOVID-19第一次救済策を承認しました。これには、バージニア州、CDC、FDA、メディケア、戦略的国家備蓄、およびCOVID-19ワクチンへの1610億米ドルが含まれています。病院経営者協会が報告した毎月500億米ドルの赤字はカバーされていないです。2020年8月、CDCはCOVID-19の原因ウイルスであるSARS-CoV-2を特定する2つの臨床検査法を開発しました。これらの検査のうち新しいものは、インフルエンザA型とB型ウイルスの検査にも使用されています。3つのウイルスを同時に検査することで、公衆衛生担当者は、不足している資源を節約しながら、地域社会におけるこれらのウイルスの蔓延を抑えるために必要な情報を得ることができます。

ラテンアメリカは、COVID-19ワクチンの世界の試験のための主要な場所となっており、地域社会に広くウイルスが存在するため、開発者はワクチンの効率性をテストすることができます。メキシコでは、フランスのサノフィ、米国の大手製薬会社ジョンソン・エンド・ジョンソン、中国の企業2社の後期臨床試験も実施されています。

競合情勢。

COVID-19緩和製品は競争が激しく、複数の大手および新規の市場プレーヤーで構成されています。世界のCOVID-19緩和製品市場には、3M Company、Abbott、Sanofi、Pfizer、Eli Lilly、Merck、3Scan、Advenio Technosys、Amara Health Analytics、Avalonなどの企業があります。主要プレイヤーは、製品の発売、臨床試験、買収、提携など、いくつかの成長戦略を採用しており、COVID-19緩和製品の世界の成長に寄与しています。例えば、2020年1月、日本光電工業は、新生児から成人までのクリティカルケア環境で必要なアプリケーションの完全なスイートを提供するNKV-550シリーズ人工呼吸器システムをデビューさせた。タッチパネルを搭載し、直感的に操作できるユーザーインターフェースと画面上のヘルプ機能を備えた人工呼吸器です。2020年4月2日、バイオテクノロジーのリーディングカンパニーであるクレスタ・インターナショナルは、手指の除菌のための高度な処方である「クレスタ・インスタント・ハンド・ハイジーンス・ソリューション」を発売しました。この斬新な製品は、抗菌性と防腐性を備えた99.9%の細菌保護を瞬時に実現し、全方位的な保護と鮮度を保つための迅速なソリューションとして確立されています。また、2020年3月には、リジェネロン社とサノフィ社が、市販の関節炎治療薬「ケブザラ（サリルマブ）」について、最大400人の患者を対象にCOVID-19コロナウイルス感染症の重症化治療として評価する米国での第II/III相臨床プログラムを開始しました。

世界のCOVID-19緩和製品市場レポートでは、約120の市場データ表、131の図、170ページへのアクセスを提供することになるであろう

目次

第1章 調査手法と範囲

  • 調査手法
  • 市場の範囲

第2章 主な動向と発展

第3章 エグゼクティブサマリー

  • 診断用製品・サービス別市場内訳
  • 集中治療製品・サービス別市場内訳
  • 医療ICT別市場内訳
  • 製薬業界製品別市場内訳
  • パーソナル＆プロテクションギア別市場内訳
  • COVID-19関連製造工場別市場内訳
  • エンドユーザー別市場内訳
  • 地域別市場内訳

第4章 市場力学

  • 市場影響要因
    • 促進要因
    • 抑制要因
    • ビジネスチャンス
  • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • バリューチェーン分析
  • 特許分析
  • 規制分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み

第7章 診断機器・サービス別

  • 血清学的検査キット
  • ロボットPCRシステム＆ソフトウェア
  • PCR機器・ソフトウェア
  • 鼻腔・口腔スワブ
  • PCR試薬・消耗品
  • 自己採取PCRテストキット
  • X線検査装置
  • その他

第8章 集中治療製品・サービス別

  • 侵襲的人工呼吸器
  • 非侵襲性人工呼吸器
  • 携帯型人工呼吸器
  • 次世代型人工呼吸器
  • 腎臓透析
  • サージキャパシティ病院・ICU
  • 体外式膜酸素供給装置
  • その他

第9章 医療ICT分野別

  • Eヘルス
  • AI、ビッグデータ、ディープラーニング
  • ブロックチェーン技術
  • 地理空間監視システム・サービス
  • 在宅医療IT
  • その他

第10章 製薬業界向け製品別

  • ワクチン
  • 治療薬
  • その他

第11章 個人用・保護具別

  • 医療用手袋
  • 医療用フェイスマスク
  • 医療用PPEガウン
  • 手指消毒剤・表面消毒剤
  • メディカルフェイスシールド
  • PPE滅菌システム＆消耗品
  • 医療用アイケア
  • その他

第12章 COVID-19関連製造工場別

  • 人工呼吸器
  • 血清学的検査キット
  • 自己採取式PCR検査キット
  • PCR試薬
  • PCRシステム
  • グローブ
  • PPEガウン
  • その他

第13章 エンドユーザー別

  • 病院
  • 救急医療サービス（EMS）
  • 臨床検査機関
  • 研究機関
  • ホームケア＆ナーシングホーム
  • クリニック
  • その他

第14章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他の欧州地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第15章 競合情勢

  • 競合シナリオ
  • 競合他社の戦略分析
  • 市況/シェア分析
  • M&A（合併・買収）分析

第16章 企業プロファイル

  • 3M Company
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Abbott
  • Agilent Technologies
  • Medtronic
  • Pfizer
  • Qualaris Healthcare Solutions
  • Allscripts Healthcare Solutions
  • Agfa Healthcare
  • AbCellera
  • 3Scan
  • Sanofi
  • Advenio Technosys
  • Siemens
  • Amara Health Analytics
  • Regeneron Pharmaceuticals
  • Avalon
  • Eli Lilly
  • Merck
  • Koninklijke Philips NV

第17章 DataM

目次
Product Code: DMPH2606

Market Overview

COVID-19 Mitigation Products Market was valued at USD YY million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of YY% during the forecast period (2022-2029).

Mitigation products reduce the risk of contamination and slow the spread of COVID-19. The COVID-19 global pandemic has increased the demand for essential mitigation products and services. COVID-19 has put pressure on MedTech and the pharmaceutical industry, with high demand for diagnostic tests, vaccines, ventilators, personal protective equipment (PPE), and other essential medical supplies. The global COVID-19 mitigation market is growing due to several factors such as rising demand for COVID-19 vaccine, growing awareness towards protection from COVID-19 globally, and rising government and non-government organization's initiatives to meet the global demand for diagnostics, protection, and other products related to COVID-19.

Market Dynamics: Increase in FDA initiative drives market growth.

With high COVID-19 emergencies, the FDA has taken several proactive steps to contact medical device manufacturers and others in the supply chain, including hospitals and group purchasing organizations. The FDA has reached over 1,000 device manufacturing sites globally, focusing on virtual devices and services. The outreach has focused on two main types of virtual devices: those that are in high demand due to the COVID-19 pandemic outbreak, such as PPE and ventilators, and devices that may be prone to a potential shortage if there is a supply disruption. The FDA issued a EUA to increase the supply of filtering facepiece respirators by authorizing certain imported disposable respirators that are not the National Institute for Occupational Safety and Health (NIOSH)-approved for use by health care professionals. Hence, with increasing such efforts and strategies to increase the availability of devices and services, the market is expected to grow over the forecast period worldwide.

Market Segmentation: The ventilator segment is projected to be the dominant segment in the market during the forecast period.

The COVID-19 Related Manufacturing Plant segmented as Ventilators, Serologic Test Kits, Self-collection PCR Test Kits, PCR Reagents, PCR Systems, Gloves, PPE Gowns and others.

Advancements in mechanical ventilators aimed to provide improved services, settle on better choices, and improve patient comfort alongside the blending of pathophysiology, medicine, and engineering to enhance the quality of medical care in respiratory distresses. To meet rising demand worldwide, all ventilator manufacturers are ramping up their production, analyzing the criticality of the situation; even other companies, such as various leading US-based car manufacturing companies, are also considering manufacturing ventilators by teaming up with ventilator manufacturing companies to set up as many units as much as possible. It is estimated that in April 2020 that over 900,000 ventilators were in demand worldwide, with a shortage of 80,000 in the U.S. alone. Major companies that provide the U.S. with the devices include General Electric Co., Medtronic PLC, Hill-Rom Holdings Inc., ResMed Inc., and Sweden's Getinge AB are adopting various strategies to meet the rising demand. For instance, in the first three months of 2020, Dragerwerk AG & Co. KGaA saw a sharp rise, increasing by 116.7%. In the medical division, orders rose by 177.2%, driven primarily by demand for ventilators. On March 30th, 2020, Smiths Group contracted with the U.K. Government for a significant ramp-up in producing its life-saving Smiths Medical paraPAC plus™ ventilators. Production is expected to grow rapidly, increasing from hundreds a month to thousands a month to fulfill 10,000 units in response to the U.K. Government's challenge to U.K. technology and engineering businesses to help save lives in the coronavirus pandemic.

In pharma industry products segment, vaccine sub segment held significant share in the market.

The pharma industry is expected to grow significantly over the forecast period due to ongoing clinical trials for the COVID-19 vaccine. In August 2020, about 172 economies were engaged in discussions to participate in COVAX, a global initiative to work with vaccine manufacturers to provide countries with equal access to safe and effective vaccines when licensed and approved. COVAX has the largest and most diverse COVID-19 vaccine portfolio globally, including nine candidate vaccines, with a further nine under evaluation and conversations underway with other major producers. COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, is co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance, and the World Health Organization (WHO), in partnership with developed and developing country vaccine manufacturers. It is the only worldwide initiative working with governments and manufacturers to ensure that COVID-19 vaccines are available globally to higher- and lower-income countries.

Geographical Penetration: North America is the dominating region during the forecast period.

The North American region is estimated to dominate the global COVID-19 mitigation products accounting for the largest market share over the forecast period. The rate of coronavirus deaths per 100,000 people in the U.S. is lower than in several European countries. By 2022, U.S. healthcare spending stood at $3.3 trillion, more than 42% of global healthcare expenditures. By March 2020, Congress approved an unprecedented $2.2 trillion COVID-19 first relief package. It includes $161 Billion to the VA, CDC, FDA, Medicare, the Strategic National Stockpile, and COVID-19 Vaccines. It does not cover the $50 billion monthly deficit reported by the Hospitals Managers Association. In August 2020, CDC developed two laboratory tests identifying SARS-CoV-2, the virus that causes COVID-19. The newer of these tests are also used to test for influenza A and B viruses. Testing for all three viruses simultaneously will provide public health officials with the information they need to help reduce the spread of these viruses in the community while conserving resources in short supply.

Latin America has become a prime location for global COVID-19 vaccine trials, with widespread viruses in the community allowing developers to test their vaccines' efficiency. Mexico also carries out late-stage trials for France's Sanofi, U.S. pharmaceutical giant Johnson & Johnson, and two Chinese companies.

Competitive Landscape:

The COVID-19 mitigation products are highly competitive and consist of several major and new market players. Some of the global COVID-19 mitigation products markets are 3M Company, Abbott, Sanofi, Pfizer, Eli Lilly, Merck, 3Scan, Advenio Technosys, Amara Health Analytics, and Avalon, among others. The major players are adopting several growth strategies such as product launches, clinical trials, acquisitions, and collaborations, contributing to the growth of the COVID-19 Mitigation Products globally. For instance, On January 2020, Nihon Kohden debuted its NKV-550 Series Ventilator System, which offers a full suite of applications necessary in a critical care setting for neonates through adults. The ventilator features an integrated touchscreen, an intuitive user interface, and on-screen help functions. On April 2nd, 2020, Clensta International, a leading biotechnology company, launched the Clensta Instant Hand Hygiene Solution, advanced formula for hand sanitization. The novel product offers instant 99.9% germ protection with antimicrobial and antiseptic properties, establishing the new product as a quick solution for all-around protection and freshness. Also, In March 2020, Regeneron Pharmaceuticals and Sanofi launched a Phase II/III clinical program in the U.S. evaluating the marketed arthritis drug Kevzara (sarilumab) as a severe treatment for COVID-19 coronavirus infection in up to 400 patients.

The global COVID-19 mitigation products market report would provide an access to approximately 120 market data tables, 131 figures and 170 pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Scope of the Market

2. Key Trends and Developments

3. Executive Summary

  • 3.1. Market Snippet by Diagnostic Products and Services
  • 3.2. Market Snippet by Intensive Care Products & Services
  • 3.3. Market Snippet by Medical ICT
  • 3.4. Market Snippet by Pharma Industry Products
  • 3.5. Market Snippet by Personal & Protection Gear
  • 3.6. Market Snippet by COVID-19 Related Manufacturing Plant
  • 3.7. Market Snippet by End-User
  • 3.8. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market impacting factors
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
  • 4.2. Impact analysis

5. Industry Analysis

  • 5.1. Porter's five forces analysis
  • 5.2. Value chain analysis
  • 5.3. Patent Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives

7. By Diagnostic Products and Services

  • 7.1. Introduction
    • 7.1.1. Market size analysis, and y-o-y growth analysis (%), By Diagnostic Products and Services Segment
    • 7.1.2. Market attractiveness index, By Diagnostic Products and Services Segment
  • 7.2. Serologic Test Kits*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 7.3. Robotic PCR Systems & Software
  • 7.4. PCR Instrumentation & Software
  • 7.5. Nose & Mouth Swabs
  • 7.6. PCR Reagents & Consumables
  • 7.7. Self-collection PCR Test Kits
  • 7.8. X-Ray Procedures
  • 7.9. Others

8. By Intensive Care Products & Services

  • 8.1. Introduction
    • 8.1.1. Market size analysis, and y-o-y growth analysis (%), By Intensive Care Products & Services Segment
    • 8.1.2. Market attractiveness index, By Intensive Care Products & Services Segment
  • 8.2. Invasive Mechanical Ventilators *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 8.3. Noninvasive Ventilators
  • 8.4. Portable Ventilators
  • 8.5. Next Generation Ventilators
  • 8.6. Kidney Dialysis
  • 8.7. Surge Capacity Hospitals & ICUs
  • 8.8. Extracorporeal Membrane Oxygenation Procedures
  • 8.9. Others

9. By Medical ICT

  • 9.1. Introduction
    • 9.1.1. Market size analysis, and y-o-y growth analysis (%), By Medical ICT Segment
    • 9.1.2. Market attractiveness index, By Medical ICT Segment
  • 9.2. E-Health *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 9.3. AI, Big Data & Deep Learning
  • 9.4. Blockchain Technologies
  • 9.5. Geo-Surveillance Systems & Services
  • 9.6. Homecare IT
  • 9.7. Others

10. By Pharma Industry Products

  • 10.1. Introduction
    • 10.1.1. Market size analysis, and y-o-y growth analysis (%), By Pharma Industry Products Segment
    • 10.1.2. Market attractiveness index, By Pharma Industry Products Segment
  • 10.2. Vaccines*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 10.3. Therapeutic Drugs
  • 10.4. Others

11. By Personal & Protection Gear

  • 11.1. Introduction
    • 11.1.1. Market size analysis, and y-o-y growth analysis (%), By Personal & Protection Gear Segment
    • 11.1.2. Market attractiveness index, By Personal & Protection Gear Segment
  • 11.2. Medical Gloves *
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 11.3. Medical Face Masks
  • 11.4. Medical PPE Gowns
  • 11.5. Hand & Surface Sanitizers
  • 11.6. Medical Face Shields
  • 11.7. PPE Sterilization: Systems & Consumables
  • 11.8. Medical Eye Protection
  • 11.9. Others

12. By COVID-19 Related Manufacturing Plant

  • 12.1. Introduction
    • 12.1.1. Market size analysis, and y-o-y growth analysis (%), By COVID-19 Related Manufacturing Plant Segment
    • 12.1.2. Market attractiveness index, By COVID-19 Related Manufacturing Plant Segment
  • 12.2. Ventilators*
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 12.3. Serologic Test Kits
  • 12.4. Self-collection PCR Test Kits
  • 12.5. PCR Reagents
  • 12.6. PCR Systems
  • 12.7. Gloves
  • 12.8. PPE Gowns
  • 12.9. Others

13. By End-User

  • 13.1. Introduction
    • 13.1.1. Market size analysis, and y-o-y growth analysis (%), By End-User Segment
    • 13.1.2. Market attractiveness index, By End-User Segment
  • 13.2. Hospitals*
    • 13.2.1. Introduction
    • 13.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 13.3. Emergency Medical Services (EMS)
  • 13.4. Clinical Labs
  • 13.5. Research Bodies
  • 13.6. Homecare & Nursing Homes
  • 13.7. Clinics
  • 13.8. Others

14. By Region

  • 14.1. Introduction
    • 14.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
    • 14.1.2. Market Attractiveness Index, By Region
  • 14.2. North America
    • 14.2.1. Introduction
    • 14.2.2. Key region-specific dynamics
    • 14.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Products and Services
    • 14.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intensive Care Products & Services
    • 14.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pharma Industry Products
    • 14.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medical ICT
    • 14.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Personal & Protection Gear
    • 14.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By COVID-19 Related Manufacturing Plant
    • 14.2.9. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 14.2.10. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 14.2.10.1. U.S.
      • 14.2.10.2. Canada
      • 14.2.10.3. Mexico
  • 14.3. South America
    • 14.3.1. Introduction
    • 14.3.2. Key Region-Specific Dynamics
    • 14.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Products and Services
    • 14.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intensive Care Products & Services
    • 14.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pharma Industry Products
    • 14.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medical ICT
    • 14.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Personal & Protection Gear
    • 14.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By COVID-19 Related Manufacturing Plant
    • 14.3.9. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 14.3.10. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 14.3.10.1. Brazil
      • 14.3.10.2. Argentina
      • 14.3.10.3. Rest of South America
  • 14.4. Europe
    • 14.4.1. Introduction
    • 14.4.2. Key Region-Specific Dynamics
    • 14.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Products and Services
    • 14.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intensive Care Products & Services
    • 14.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pharma Industry Products
    • 14.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medical ICT
    • 14.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Personal & Protection Gear
    • 14.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By COVID-19 Related Manufacturing Plant
    • 14.4.9. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 14.4.10. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 14.4.10.1. Germany
      • 14.4.10.2. U.K.
      • 14.4.10.3. France
      • 14.4.10.4. Spain
      • 14.4.10.5. Italy
      • 14.4.10.6. Rest of Europe
  • 14.5. Asia Pacific
    • 14.5.1. Introduction
    • 14.5.2. Key Region-Specific Dynamics
    • 14.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Products and Services
    • 14.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intensive Care Products & Services
    • 14.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pharma Industry Products
    • 14.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medical ICT
    • 14.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Personal & Protection Gear
    • 14.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By COVID-19 Related Manufacturing Plant
    • 14.5.9. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 14.5.10. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 14.5.10.1. China
      • 14.5.10.2. India
      • 14.5.10.3. Japan
      • 14.5.10.4. Australia
      • 14.5.10.5. Rest of Asia Pacific
  • 14.6. Middle East and Africa
    • 14.6.1. Introduction
    • 14.6.2. Key Region-Specific Dynamics
    • 14.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Products and Services
    • 14.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Intensive Care Products & Services
    • 14.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pharma Industry Products
    • 14.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medical ICT
    • 14.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Personal & Protection Gear
    • 14.6.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By COVID-19 Related Manufacturing Plant
    • 14.6.9. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

15. Competitive Landscape

  • 15.1. Competitive scenario
  • 15.2. Competitor strategy analysis
  • 15.3. Market positioning/share analysis
  • 15.4. Mergers and acquisitions analysis

16. Company Profiles

  • 16.1. 3M Company*
    • 16.1.1. Company Overview
    • 16.1.2. Product Portfolio and Description
    • 16.1.3. Key Highlights
    • 16.1.4. Financial Overview
  • 16.2. Abbott
  • 16.3. Agilent Technologies
  • 16.4. Medtronic
  • 16.5. Pfizer
  • 16.6. Qualaris Healthcare Solutions
  • 16.7. Allscripts Healthcare Solutions
  • 16.8. Agfa Healthcare
  • 16.9. AbCellera
  • 16.10. 3Scan
  • 16.11. Sanofi
  • 16.12. Advenio Technosys
  • 16.13. Siemens
  • 16.14. Amara Health Analytics
  • 16.15. Regeneron Pharmaceuticals
  • 16.16. Avalon
  • 16.17. Eli Lilly
  • 16.18. Merck
  • 16.19. Koninklijke Philips NV
  • List not Exhaustive*

17. DataM

  • 17.1. Appendix
  • 17.2. About us and services
  • 17.3. Contact us